BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Amgen Incorporated

Over the past quarter century, Amgen has pioneered the methods by which human proteins that play a role in disease processes are identified, isolated, produced in quantity and used as therapeutics. Today, Amgenhas research programs in inflammation, metabolic disorders and osteoporosis, neurology, oncology and hematology. The company has R&D facilities in Thousand Oaks, CA; San Francisco, CA; Cambridge, MA; Cambridge, UK; Regensburg, Germany; and Seattle, WA.

With expertise in proteins, small molecules, antibodies, peptibodies, and nucleic acids, Amgen’s scientists can pursue the study of disease, choose the best target for a disease and then use the modality most likely to have an effect on that target. This approach positions Amgen as one of the only companies with capabilities across a range of modalities.

Mastering the tools of therapeutic development, as they emerge, is crucial to Amgen’s ongoing success. Accordingly, the company has invested at least 20 percent of product sales in research and development each year since 1994—a total of approximately $2.0 billion in 2004.


Contact Details:
One Amgen Center Drive
Thousand Oaks
CA
91320 1799
United States of America
Tel:805 447 1000
Fax:805 447 1010
Email:
WWW:

www.amgen.com/




Loading...

Recent Publications by Amgen Incorporated:

[Hemoglobin variability in chronic renal failure patients.]
In recent years, the question of hemoglobin (Hb) stability in patients...
10th October, 2008
Amgen Kft. Orvostudomanyi Osztaly Budapest Szabadsag ter 7. 1054. Orv Hetil. 2008 Oct 12;149(41):1925-34.
DOI Direct Link
Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
BACKGROUND: Inflammation in an ESRD patient may impact responsiveness to...
9th October, 2008
1Department of Biostatistics and Epidemiology, Amgen Inc., Thousand Oaks, Nephrol Dial Transplant. 2008 Oct 7.
DOI Direct Link
Supercritical fluid chromatography comparison of the poly(trans-1,2-cyclohexanediyl-bis acrylamide) (P-CAP) column with several derivatized polysaccharide-based stationary phases.
The poly(trans-1,2-cyclohexanediyl-bis acrylamide) (P-CAP) column has so...
8th October, 2008
Discovery Analytical Sciences, Molecular Structure, Chemistry Research and J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 16.
DOI Direct Link
Chemical Reactivity of Methoxy 4-O-Aryl Quinolines: Identifcation of Glutathione Displacement Products in Vitro and in Vivo.
AMG 458 {1-(2-hydroxy-2-methylpropyl)-...
8th October, 2008
Pharmacokinetics and Drug Metabolism and Medicinal Chemistry, Amgen, Inc., Chem Res Toxicol. 2008 Oct 7.
DOI Direct Link
Re-estimating the sample size of an on-going blinded trial based on the method of randomization block sums.
We extend a method we had previously described (Statist. Med. 2005) to...
7th October, 2008
Amgen Inc., 1120 Veterans Blvd., South San Francisco, CA 94080, U.S.A. Stat Med. 2008 Oct 6.
DOI Direct Link

View more Amgen Incorporated research publications.

BioNews Results for Amgen Incorporated:

District Court Affirms Patent Infringement Rulings and Finds That Amgen is Entitled to a Permanent Injunction
Pharma Live:  Oct 5 2008 9:10PM Matching: amgen
Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology
Pharma Live:  Oct 4 2008 1:00AM Matching: amgen
Judge Says Amgen Entitled to Permanent Injunction in EPO Case
Calibre Macro World:  Oct 4 2008 12:02AM Matching: amgen
Judge Says Amgen Entitled to Permanent Injunction in EPO Case
TMC Net:  Oct 4 2008 1:30AM Matching: amgen
Armstrong to compete in Tour of California
Atascadero News:  Oct 3 2008 10:41PM Matching: amgen
Promote your company here: BioNewsCast - Press Release Distribution

View more Amgen Incorporated news.

Amgen Incorporated Patents:

US Patent No.Title
7314728 Methods of treating peripheral arterial occlusions
7335743 Human anti-IFN-.gamma. neutralizing antibodies as selective IFN-.gamma. pathway inhibitors
7348162 Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereof
7354583 Antibody-induced apoptosis
7354938 Pyrazole compounds and uses related thereto

View more Amgen Incorporated patents.

Amgen Incorporated (AMGN) Financial information Links from Barchart

AMGN Quote from from Barchart.com
AMGN Chart from from Barchart.com
AMGN Profile from from Barchart.com
AMGN Opinion from from Barchart.com

View more Amgen Incorporated finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 366 individuals from Amgen Incorporated using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 814 times since April 2007, the link to the organisation's website has been followed 99 times

Recent Search Terms used to find this page: one amgen center drive building 27 | department of neuroscience amgen | Amgen Financial Reports in Excel | amgen and world kidney day | Amgen med chem | @amgen contact email uk | @amgen contact email uk | department of early development medical sciences amgen | amgen peptibodies | amgen VAT | .

Search for more companies in Thousand Oaks

Search for more companies in CA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Amgen Incorporated
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.